Search | IOVS | ARVO Journals

View

Showing 1 – 13 of 13

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract May 2006

Comparison of Systemic and IOP Effects With Intravenous or Topical WIN 55–212–2

M.H. Oltmanns; S.S. Samudre; F.A. Lattanzio, Jr.; R.C. Allen; B.R. Martin; I.G. Castillo

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):401. doi:

ARVO Annual Meeting Abstract May 2006

Extended Treatment With Lacritin, a Novel Tear Glycoprotein, Stimulates Tear Production in Rabbits

A.R. Spitze; J.D. Sheppard, Jr.; P.B. Williams; K. Pelosky; G.W. Laurie; R.L. McKown; F.A. Lattanzio, Jr.

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):5581. doi:

ARVO Annual Meeting Abstract May 2006

Telemetric Measurement Of Intraocular Pressure In A Rabbit Model

F.A. Lattanzio, Jr.; A. Hosseini; T. Delahanty; P.G. Loose–Thurman; P.B. Williams

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):1234. doi:

ARVO Annual Meeting Abstract May 2006

Novel Endocannabinoids Confer Neuroprotection in NMDA Rat Model

S.S. Samudre; P.B. Williams; B.R. Martin; I.G. Castillo; A. Hosseini; F.A. Lattanzio, Jr.

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):1566. doi:

ARVO Annual Meeting Abstract May 2005

Omalizumab Improves Symptoms of Severe Ocular Allergy

P.B. Williams; D.J. Simon; J.D. Sheppard, Jr; F.A. Lattanzio, Jr

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):942. doi:

ARVO Annual Meeting Abstract May 2005

Human Corneal Penetration by Topical Formulations of the Synthetic Endocannabinoid, WIN 55–212–2

A.R. Spitze; F.A. Lattanzio, Jr; R.C. Allen; I. Castillo; P.B. Williams

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):3783. doi:

ARVO Annual Meeting Abstract May 2005

Chronic Application of Topical WIN 55–212–2 in a Rat Glaucoma Model

S.S. Samudre; D. Tibbs; F.A. Lattanzio, Jr; R.C. Allen; I. Castillo; P. Loose–Thurman; E.R. Crouch, Jr

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):3784. doi:

ARVO Annual Meeting Abstract May 2004

Development of a Stable Rat Ocular Hypertension Model

S.S. Samudre; I.G. Castillo; A. Hosseini; F.A. Lattanzio, Jr.; R.C. Allen; P.B. Williams

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):4448. doi:

ARVO Annual Meeting Abstract May 2004

Botulinum Toxin–induced Ptosis as Treatment for Childhood Amblyopia

E.R. Crouch; T.A. Theobald; F.A. Lattanzio, Jr.; P.B. Williams; M.L. Frank

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):4995. doi:

ARVO Annual Meeting Abstract May 2004

Topical Win55 212–2 Reduces Intraocular Pressure in Ocular Hypertensive Rats

M.H. Oltmanns; F.A. Lattanzio, Jr.; R.C. Allen; I.G. Castillo; P.B. Williams; A.H. Lichtman

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):2093. doi:

ARVO Annual Meeting Abstract May 2004

In Normal Rabbits, Topical WIN–55–212–2 Decreases IOP Without Effect on Heart Rate and Blood Pressure

K. Pratap; F.A. Lattanzio, Jr.; R.C. Allen; P. Loose–Thurman; E.R. Crouch, Jr.

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):2098. doi:

ARVO Annual Meeting Abstract May 2003

Does Confocal Microscopy Effectively Predict Cellular Effects of Steroid-treated Acute Uveitis?

S.S. Samudre; F.A. Lattanzio, Jr.; P.G. Loose-Thurman; J.D. Sheppard, Jr.

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):727. doi:

ARVO Annual Meeting Abstract May 2003

Primate Model for Penetrating Keratoplasty

P.B. Williams; D.A. Fellner; F.A. Lattanzio, Jr.; J.D. Sheppard, Jr.

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):1392. doi:

Advertisement